<?xml version="1.0" encoding="UTF-8"?>
<p>Sarilumab is another human monoclonal antibody against the interleukin-6 receptor. It binds to soluble and membrane-bound IL-6 receptors and inhibits IL-6-mediated signaling via these receptors. There is a growing body of evidence confirming the benefit of targeting the IL-6 pathway in patients with COVID-19, most notably in a recent single-arm study in China with tocilizumab in critically ill COVID-19 patients [
 <xref rid="B94-pharmaceuticals-13-00096" ref-type="bibr">94</xref>]. 
</p>
